Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Therapeutics presented positive Phase 2 long-term extension data for sutacimig in Glanzmann Thrombasthenia, demonstrating a 62% reduction in high-intensity bleed rates and an 84% reduction in treated bleeds for the low-dose weekly cohort. Based on the durable efficacy and manageable safety profile, the FDA has aligned on a Phase 3 dose of 0.2mg/kg weekly, with initiation planned for the second half of 2026.
Key figures
- Drug Name
- Sutacimig
- Phase Of Trial
- Phase 2 long-term extension (LTE)
- Phase 3 dose
- 0.2mg/kg weekly
- Patient count
- 34
- Grade 2 te events
- 3
- Max exposure months
- 15.9
- Median exposure months
- 6.9
- Fviid variant binding pct
- 88%
- Phase 3 initiation timeline
- 2H 2026
- Bleed reduction high intensity pct
- 62%
- Bleed reduction low dose weekly pct
- 84%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.